WO2009058613A1 - Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid - Google Patents
Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid Download PDFInfo
- Publication number
- WO2009058613A1 WO2009058613A1 PCT/US2008/080596 US2008080596W WO2009058613A1 WO 2009058613 A1 WO2009058613 A1 WO 2009058613A1 US 2008080596 W US2008080596 W US 2008080596W WO 2009058613 A1 WO2009058613 A1 WO 2009058613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- lndica
- composition
- skin
- synthesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the field of the invention relates to the use of plant and seed extracts for the treatment of skin.
- the present invention involves the use of plant and seed extracts, for example, Chia Seed oil and extracts of Opuntia Ficus Indica, to increase the synthesis of cell proteins and macromolecules.
- Collagen is the most abundant protein in the human body and is the main component of connective tissue. Collagen is found in cartilage, bone, ligaments, tendon, teeth, and skin. Pro-collagen, the pre-processed form of collagen, is assembled in cells, and consists of three polypeptide chains that form a triple helix stabilized by intramolecular bonding. The triple helical pro-collagen molecule is then modified in the cell and is secreted into the extracellular matrix, where it is further processed to a mature form (tropocollagen). Mature collagen molecules then come together to form collagen fibrils, and collagen fibrils come together to form collagen fibers. The resulting collagen fibers have great tensile strength.
- Collagen is a critical component of skin, and, as a result of its structure, contributes to the strength, structure and firmness of skin. Loss of collagen in the skin, typically via enzymatic degradation, is a major factor in the causation of skin wrinkling and the aged appearance of the skin.
- Hyaluronic acid is a non-sulfated glycosaminoglycan found in connective, epithelial and neural tissue, and is a major component of the cutaneous extracellular matrix.
- Hyaluronic acid is synthesized by a class of integral membrane proteins and is secreted into the extracellular matrix.
- Hyaluronic acid is a polymer of repeated disaccharides of D-glucuronic acid and N-acetylglucosamine; this high carbohydrate content makes it a 'sticky molecule 1 , and as a result, it attracts water, therefore contributing to tissue hydration, lubrication, resistance to compression, and cellular function.
- Hyaluronic acid can be approximately 25,000 disaccharide repeats in length.
- Hyaluronic acid's hydrating properties result in increased smoothness, softening and decreased lines and wrinkles in the skin.
- Hyaluronic acid levels decrease due to aging and exposure to ultraviolet radiation, and reduction of hyaluronic acid levels results in the wrinkling of skin.
- lnterleukin-1 b is a cell signaling molecule that is a member of the interleukin 1 cytokine family. It is produced by activated macrophages as a proprotein, and is proteolytically cleaved, resulting in its active form. This cytokine is an important mediator of the inflammatory response. Increased inflammation of the skin causes redness and swelling.
- the present invention is a method comprising administering a composition comprising chia seed oil, an extract of opuntia ficus, or both to improve the moisture, texture and appearance of the skin by increasing the synthesis of skin proteins, such as collagen, and of macromolecules found in the extracellular matrix of the skin, such as hyaluronic acid. Additionally, the present invention involves the use of Chia Seed Oil and/or a lipophilic extract of Opuntia Ficus lndica to decrease the synthesis of lnterleukin-1 b. Methods of the present invention can include a step of topical administration or of oral administration.
- the invention is a formulation comprising Chia Seed oil. More preferably, the invention is a composition comprising Chia Seed oil and one or more of the following: safflower seed (Carthamus tinctorius) oil; Butylated hydroxytoluene (BHT); meadowfoam seed oil; sesame seed (seamum indicum) oil; mineral oil; squalane; shea butter (butyrospermum parkii) oil; tocopheryl acetate; fragrance; borage oil; or rice bran oil.
- the invention is a method of using this composition to stimulate collagen synthesis, to decrease synthesis of lnterleukin-1 b, or both.
- Another example of the invention is a method for increasing collagen synthesis in a skin cell comprising administering a composition comprising Chia Seed oil to the skin cell, wherein the Chia Seed oil increases collagen synthesis in the skin cell.
- the invention is a method of improving the appearance, texture, or moisture of skin by administering a formulation comprising Chia Seed oil to the skin, wherein the Chia Seed oil increases collagen synthesis, decreases the synthesis of lnterleukin-1 b, or both.
- a further example of the invention is a method for decreasing lnterleukin-1 b synthesis in a skin cell comprising administering a composition comprising Chia Seed oil to the skin, wherein the Chia Seed oil decreases lnterleukin-1 b synthesis in the skin cell.
- Another example of the invention is a formulation comprising Opuntia Ficus lndica extract.
- a further example of the invention is a method for increasing the synthesis of hyaluronic acid in a skin cell comprising administering a composition comprising Opuntia Ficus lndica extract to the skin wherein the Opuntia Ficus lndica extract increases hyaluronic acid synthesis in the skin cell.
- a further example of the invention is a method for increasing synthesis of collagen in a skin cell comprising administering a composition comprising Opuntia Ficus lndica extract to the skin, wherein the Opuntia Ficus lndica extract increases collagen synthesis in the skin cell.
- a further example of the invention is a method for decreasing lnterleukin-1 b synthesis in a skin cell comprising administering a composition comprising a lipophilic extract of Opuntia Ficus lndica to the skin, wherein the Opuntia Ficus lndica extract decreases lnterleukin-1 b synthesis in the skin cell.
- An additional example of the invention is a method of improving the appearance, texture, or moisture of skin by administering a formulation comprising Opuntia Ficus lndica extract to the skin, wherein the Opuntia Ficus lndica extract increases collagen synthesis in the skin, increases hyaluronic acid synthesis in the skin, or both.
- An additional example of the invention is a method of improving the appearance, texture, or moisture of skin by administering a formulation comprising a lipophilic Opuntia Ficus lndica extract to the skin, wherein the lipophilic Opuntia Ficus lndica extract decreases lnterleukin-1b synthesis in the skin.
- Another example of the invention is a formulation comprising Chia Seed oil and/or Opuntia Ficus lndica extract. More preferably, the invention is a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of water; polyquaternium-10; methylparaben; Polyethylene glycol (PEG)-8; disodium lauroamphodacetate; sodium trideceth sulfate; hexylene glycol; sodium methyl cocoyl taurate; tea-lauryl sulfate; lauryl betaine; sodium myristoyl sarcosinate; Polyethylene glycol (PEG)-150 distearate; citric acid- anhydrous; sodium citrate-dihydrate; diazolidinyl urea; and fragrance.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/or hyaluronic acid synthesis in the skin or to decrease IL-
- An additional example of the present invention is a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of water; disodium EDTA; methylparaben; propylparaben; glycerin; polysorbate 60; panthenol; isopropyl palmitate; octyl palmitate; C12-15 alkyl benzoate; dipropylene glycol dibenzoate; PPG-15 stearyl ether benzoate; isododecane; isoeicosane; squalane; shea butter (butylspermum parkii) oil; jojoba oil; dimethicone; glyceryl stearate; PEG-100 stearate; cetyl alcohol; butylene glycol; chlorphenesin; fragrance; polyacrylamide; C13-14 isoparaffin; and Laureth-7.
- the present invention comprises a method of administering the present invention
- Another example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of water; glycerin; aloe vera powder; panthenol; methylparaben; propylparaben; hydroxyethylacrylate; sodium acryloyldimethyl taurate copolymer; polysorbate 60; squalane; behenyl alcohol; cetyl alcohol; tocopheryl acetate; isodecyl neopentanoate; glyceryl trioctanoate; cetearyl alcohol; cetearyl glucoside; dimethicone; butylene glycol; chlorphenesin; chamomilla recutita flower extract; biosaccharide gum-1; pentadecalactone; and dipropylene glycol.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/or h
- Another example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of cyclomethicone; polyethylene glycol (PEG)/PPG-18/18 dimethicone; cyclopentasiloxane; disteardimonium hectorite; SD alcohol 40; phenoxyethanol; methylparaben; ethylparaben; propylparaben; trimethylsiloxysilicate; zinc oxide; triethoxycaprylysilane; micronized titanium dioxide; titanium dioxide; iron oxides (yellow; red; black; etc.); caprylysilane; purified water; and sodium chloride.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/or hyaluronic acid synthesis in the skin or to decrease IL-Ib synthesis in the skin.
- a further example of the present invention is a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of diisopropyl dimer dilinoleate; squaiane; cyclomethicone; phenoxyethanol; propylparaben; cyclomethicone; polyethylene glycol (PEG)/PPG-18/18 dimethicone; trimethylsiloxysilicate; cyclopentasiloxane; disteardimonium hectorite; SD alcohol 40; titanium dioxide; aluminum hydroxide; stearic acid; caprylysilane; zinc oxide; triethoxycaprylysilane; iron oxides (yellow; red; black; etc.); polyethelene beads; purified water; sodium chloride; butylene glycol; methylparaben; and glycerin.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/
- Another example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of purified water; C12-15 alkl benzoate; acrylates/C 10-30 alkyl acrylate; xanthan gum; methylparaben; butylene glycol; glycerin; sorbitan laurate; panthenol; behenyl alcohol; petrolatum; squalane; isopropyl isostearate; dimethicone; arginine; phenoxyethanol; propylparaben; ethylparaben; and fragrance.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/or hyaluronic acid synthesis in the skin or to decrease IL-Ib synthesis in the skin.
- Another example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of purified water; sodium EDTA; glycerin; methylparaben; propylparaben; panthenol; sodium acrylate/acryloyldimethyl taurate copolymer; isohexadecane; polysorbate 80; hydroxyethylacrylate/sodium acryloyldimethyl taurate copolymer; squalane; polysorbate 60; C12-15 alkyl benzoate; dipropylene glycol dibenzoate; PPG-15 stearyl ether benzoate; octinoxate (octyl methoxycinnimate); oxybenzone; dicaprylyl ether; isodecyl neopentanoate; zinc oxide; triethoxycaprylysilane; tocopheryl acetate; cety
- a further example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of purified water; disodium EDTA; xanthan gum; glycerin; panthenol; methyl methacrylate crosspolymer; silica; HDI/trimethylol hexyllactone crosspolymer; silica; C12-15 alkyl benzoate; isodecyl neopentanoate; octinoxate (octyl methoxycinnimate); cetearyl alcohol; coco-glucoside; C20-22 alkyl phosphate; C20-22 alcohols; oxybenzone; zinc oxide; triethoxycaprylylsilane; palmitoyl proline; magnesium palmitoyl glutamate; sodium palmitoyl sarcosinate; cyclopentasiloxane; C30-45 alkyl
- a further example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of purified water; glycerin; disodium EDTA; panthenol; sodium citrate; citric acid; butylene glycol; chlorphenesin; methylparaben; ceteth-20; and fragrance.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/or hyaluronic acid synthesis in the skin or to decrease IL-1 b synthesis in the skin.
- a further example of the present invention is a composition
- a composition comprising Chia Seed oil and/or Opuntia Ficus lndica extract and one or more of purified water; sodium magnesium silicate; methyl gluceth-20; dimethly isosorbide; panthenol; silica; SD alcohol 40-B; salicylic acid; methylparaben; chlorphenesin; ceteth-20; fragrance; witch hazel; and glycerin.
- the present invention comprises a method of administering the aforementioned composition to increase collagen and/or hyaluronic acid synthesis in the skin or to decrease IL-Ib synthesis in the skin.
- Another example of the invention is a method for increasing collagen synthesis in a skin cell comprising administering a composition comprising Chia Seed oil and Opuntia Ficus lndica extract to the skin cell, wherein the Chia Seed oil and Opuntia Ficus lndica extract increase collagen synthesis in the skin cell.
- An additional example of the invention is a method of improving the appearance, texture, or moisture of skin comprising administering a composition of Chia Seed oil and Opuntia Ficus lndica extract to the skin, wherein the Chia Seed oil and Opuntia Ficus lndica extract increase collagen synthesis, increase hyaluronic acid synthesis or both.
- An additional example of the invention is a method of improving the appearance, texture, or moisture of skin by administering a composition Chia Seed oil and a lipophilic Opuntia Ficus lndica extract to the skin, wherein the Chia Seed oil and/or Opuntia Ficus lndica extract increase collagen synthesis, increase hyaluronic acid synthesis, and/or decrease lnterleukin-1b synthesis, or all three.
- the present invention is based on the surprising effect of unique ingredients on improving skin moisture, texture, and appearance. More specifically, the present invention is a method of using unique ingredients, for example, Chia Seed oil and/or Opuntia Ficus lndica extract, to improve skin moisture, texture, and appearance by increasing the synthesis of skin proteins such as collagen, or extracellular macromolecules such as hyaluronic acid.
- unique ingredients for example, Chia Seed oil and/or Opuntia Ficus lndica extract
- Chia Seed oil is extracted from Chia Seeds ⁇ Salvia hispanica). Chia is grown commercially for its seed, a food that is very rich in Omega 3 fatty acids (for example, alpha-linolenic acid). Historically, Chia Seeds served as a staple food of the Aztec cultures of Central Mexico. Chia sprouts are used in a similar manner as alfalfa sprouts in salads, sandwiches and other dishes. Omega 3 is an essential fatty acid (EFA) found in Chia oil. EFA's are essential for regulating healthy skin. EFA's cannot be produced by the human body and must be supplemented via diet, or by direct application. In cosmetics, alpha-linolenic acid shows benefits such as anti-inflammatory and anti-allergic properties.
- EFA essential fatty acid
- Chia Seed oil in cosmetics and skin creams, and in wound healing has been disclosed (e.g., U.S. Patent 6,497,889 and U.S. Patent Application 2004/0022839)
- the present invention is based on the surprising discovery that chia seed oil can increase collagen synthesis, and decrease lnterleukin-1b synthesis.
- the pulp from Opuntia Ficus lndica is known to contain carbohydrates like glucose and fructose. Glucose and fructose are humectant type ingredients that help hold moisture in the skin.
- the pulp from the Opuntia leaves has been historically used as an ointment and the young leaf like stems have also been ground and applied as a poultice to allay heat and inflammation.
- the fruits and young stems of Opuntia Ficus lndica are also used as a food source.
- Opuntia Ficus lndica extract for cosmetic and dermatologic applications has been disclosed (e.g., U.S. Patent 6,555,118), the present invention is based on the surprising discovery that Opuntia Ficus lndica extract can increase hyaluronic acid synthesis and that a lipophilic extract of Opuntia Ficus lndica can decrease lnterleukin-1b synthesis.
- each of the extracts used in the present invention is commercially available, there are numerous extraction methods that can be used to produce an extract to be used in the present invention. Some examples of extraction methods that can be used to produce an extract to be used in the present invention are described below. Other examples are known and described in the art, including in various publications and patents. The extraction methods described more fully below are exemplary and one of ordinary skill in the art will appreciate that other extraction techniques and methods may be used to obtain an extract useful in the present invention.
- Botanical compounds in particular can be obtained via numerous extraction methods, including maceration/solvent, digestion, percolation, and expression/compression/squeezing.
- Solvents for extraction can be broadly classified as polar (hydrophilic) or non-polar (lipophilic), and examples of solvents include ethyl alcohol, ether, and acetone. Water also may be used as an extract solvent.
- an extract useful in the unique compositions of the present invention might be obtained using an aqueous solvent extraction technique. More specifically, an extract useful in the present invention, such as Opuntia Ficus lndica extract, can be produced by extracting Opuntia Ficus lndica pads with an aqueous solvent, for example, water. Other parts of Opuntia Ficus lndica plants including the stem, leaves, roots, fruit, rind, etc. may be extracted to yield an Opuntia Ficus lndica extract useful in compositions and methods of the present invention.
- an extract useful in the present invention such as Opuntia Ficus lndica extract
- an aqueous solvent for example, water.
- Other parts of Opuntia Ficus lndica plants including the stem, leaves, roots, fruit, rind, etc. may be extracted to yield an Opuntia Ficus lndica extract useful in compositions and methods of the present invention.
- Total hydro-ethanolic extraction techniques might also be used to obtain an extract useful in the unique compositions of the present invention. Generally, this is referred to as a lump-sum extraction.
- the extract generated in this process will contain a broad variety of phytochemicals present in the extracted material including fat and water solubles. Following collection of the extract solution, the solvent will be evaporated, resulting in the extract. In one example, Opuntia Ficus lndica extract might be extracted using this technique.
- Total ethanol extraction may also be used in the present invention.
- This technique uses ethanol, rather than hydro-ethanol, as the solvent.
- This extraction technique generates an extract that may include fat soluble and/or lipophilic compounds in addition to water soluble compounds.
- An extract of Opuntia Ficus lndica might be obtained using this technique.
- An Opuntia Ficus lndica extract obtained using this method extraction may be used in compositions and methods of the present invention to decrease lnterleukin-1b synthesis.
- SFE supercritical fluid carbon dioxide extraction
- the material to be extracted is not exposed to any organic solvents. Rather, the extraction solvent is carbon dioxide, with or without a modifier, in supercritical conditions (> 31.3°C and > 73.8 bar).
- temperature and pressure conditions can be varied to obtain the best yield of extract.
- This technique generates an extract of fat soluble and/or lipophilic compounds, similar to the total hexane and ethyl acetate extraction technique described above.
- An Opuntia Ficus lndica extract obtained using this method extraction may be used in compositions and methods of the present invention to decrease lnterleukin-1b synthesis.
- Opuntia Ficus lndica extract and Chia Seed oil do not involve ethanol extractions.
- an Opuntia Ficus lndica extract may be obtained by using water at room temperature.
- a Chia Seed oil useful in the present invention may be obtained through cold pressing of Chia Seeds. The Chia Seeds may be separated from other plant materials prior to the extraction.
- Chia Seed oil can be obtained commercially from suppliers such as Green Grown Products, Inc. (http://www.greengrownproducts.com/Chia-Seed-meal- oil.htm#Chiaoil).
- Opuntia Ficus lndica extract can also be commercially obtained from suppliers such as Hangzhou New Asia International Co. Ltd. (http://www.tradekey.com/selloffer view/id/406281. htm).
- formulations of the present invention are designed to offer a combination of ingredients, in addition to the plant or seed extracts.
- formulations of the present invention comprise a unique combination of ingredients that target a number of key molecules involved in skin health, and also modulate cellular activity of skin cells to promote improved skin health.
- ingredients comprising the formulations of the present invention stimulate synthesis of collagen and/or hyaluronic acid.
- Chia Seed oil and Opuntia Ficus lndica extract are inducers of collagen synthesis, alone or in combination, and Opuntia Ficus lndica is an inducer of hyaluronic acid synthesis, while Chia Seed oil and the lipophilic extract of Opuntia Ficus lndica are effective at inhibiting the synthesis of lnterleukin-1b.
- stimulating collagen synthesis is used in its broadest sense and refers to the production of collagen, its incorporation into collagen-containing tissue (including, e.g., the synthesis, processing, cross- linking, secretion, and assembly of collagen fibrils) and the presence of healthy collagen-containing tissue.
- Stimulating or “inducing” collagen synthesis, therefore, refers to the ability of a formulation described herein to positively affect the production of collagen. Stimulating collagen synthesis may be brought about by the ability of the formulations described herein to promote steps, such as biochemical steps, leading to the formation of collagen fibrils.
- stimulating hyaluronic acid synthesis is used in its broadest sense and refers to the production of hyaluronic acid, its incorporation into hyaluronic acid-containing tissue (including, e.g., the synthesis, secretion, processing, and assembly of hyaluronic acid molecules) and the presence of healthy hyaluronic acid-containing tissue.
- Stimulating or “inducing" hyaluronic acid synthesis therefore, refers to the ability of a formulation described herein to positively affect the production of hyaluronic acid. Stimulating hyaluronic acid synthesis may be brought about by the ability of the formulations described herein to promote steps, such as biochemical steps, leading to the formation of hyaluronic acid molecules.
- the formulation comprises the approximately 0.001-30% Chia Seed oil and approximately 0.01-15% Opuntia Ficus lndica extract.
- the formulation comprises approximately 0.001-30% Chia Seed oil. More preferably, the range of Chia Seed oil is approximately 1-5%.
- the formulation comprises approximately 0.01-15% Opuntia Ficus lndica extract. More preferably, the range of Opuntia Ficus lndica extract is approximately 0.5 to 3.0%
- the formulations of the present invention are administered with an acceptable carrier.
- the formulation of the present invention could be externally administered with an acceptable carrier in the form of a gel, lotion, cream, tonic, emulsion, etc.
- the formulation of the present invention could be internally administered with an acceptable carrier in the form of a pill, tablet, powder, bar, beverage, etc.
- the formulations described herein are useful in a wide variety of finished products, including pharmaceutical products, food products, and beverage compositions.
- the products are useful for providing mammalian skin with an improved texture, appearance, and increased moisture.
- the liquid may be water-based, milk-based, tea-based, fruit juice-based, or some combination thereof.
- Solid and liquid formulations for internal administration according to the present invention can further comprise thickeners, including xanthan gum, carboxymethyl-cellulose, carboxyethylcellulose, hydroxypropylcellulose, methylcellulose, microcrystalline cellulose, starches, dextrins, fermented whey, tofu, maltodextrins, polyols, including sugar alcohols (e.g., sorbitol and mannitol), carbohydrates (e.g.
- lactose propylene glycol alginate
- gellan gum guar
- pectin tragacanth gum
- gum acacia locust bean gum
- gum arabic gum arabic
- gelatin as well as mixtures of these thickeners.
- These thickeners are typically included in the formulations of the present invention at levels up to about 0.1%, depending on the particular thickener involved and the viscosity effects desired.
- the solid and liquid (food and beverage) formulations of the present invention can, and typically will, contain an effective amount of one or more sweeteners, including carbohydrate sweeteners and natural and/or artificial no/low calorie sweeteners.
- the amount of the sweetener used in the formulations of the present invention will vary, but typically depends on the type of sweetener used and the sweetness intensity desired.
- the formulations of the present invention are topically administered in the form of a: solution, gel, lotion, cream, ointment, oil- in-water emulsion, water-in-oil emulsion, stick, spray, paste, mousse, tonic, foundation, or other cosmetically and topically suitable form.
- formulations of the present invention that are suitable for topical administration are mixed with an acceptable carrier.
- An acceptable carrier may act variously as solvent, carrier, diluent or dispersant for the constituents of the composition, and allows for the uniform application of the constituents to the surface of the skin at an appropriate dilution.
- the acceptable carrier may also facilitate penetration of the composition into the skin.
- the acceptable carrier forms from about 70% to about 99.99% by weight of the total composition. In other examples, the acceptable carrier will form from about 85% to 99.99% by weight of the total composition. The acceptable carrier may also form from about 90% to about 99.99% by weight of the total composition; or from about 99.95% to about 99.999% by weight of the total composition.
- the acceptable carrier can, in the absence of other cosmetic adjuncts or additives, form the balance of the composition.
- the various ingredients used in practicing the present invention may be soluble or insoluble in the acceptable carrier. If all ingredients of a formulation are soluble in the acceptable carrier, then the vehicle acts as solvent. However, if all or some ingredients of a formulation are insoluble in the acceptable carrier, then those ingredients are dispersed in the vehicle by means of, for example, a suspension, emulsion, gel, cream or paste, and the like.
- acceptable carriers can be emulsions, lotions, creams, or tonics.
- Acceptable carriers can comprise water, ethanol, butylene glycol, or other various solvents that aid in penetration of the skin.
- the acceptable carrier used in practicing the present invention comprises water and ethanol.
- the acceptable carrier also contains butylene glycol.
- the acceptable carrier can comprise 2-5% butylene glycol by weight of the composition.
- this acceptable carrier is mixed with a formulation of the present invention comprising 2% by weight of the total composition.
- the acceptable carrier is mixed with a formulation of the present invention comprising 0.001% to 30% by weight of the total composition; 1% to 5% by weight of the total composition; 0.01% to 15% by weight of the total composition; or 0.5% to 1.0% by weight of the total composition.
- acceptable carriers may comprise, but are not limited to comprising, any of the following examples: water; castor oil; ethylene glycol monobutyl ether; diethylene glycol monoethyl ether; corn oil; dimethyl sulfoxide; ethylene glycol; isopropanol; soybean oil; glycerin; soluble collagen; safflower seed oil; meadowfoam seed oil; mineral oil; squalene; shea butter; borage oil; or rice bran oil; polyquaternium-10; methylparaben; PEG-8; disodium lauroamphodacetate; sodium trideceth sulfate; hexylene glycol; sodium methyl cocoyl taurate; tea-lauryl sulfate; lauryl betaine; sodium myristoyl sarcosinate; PEG-150 distearate; citric acid-anhydrous; sodium citrate-dihydrate; diazolidinyl
- acceptable carriers used in the present invention may optionally comprise one or more humectants, including but not limited to: dibutyl phthalate; soluble collagen; sorbitol; or sodium 2-pyrrolidone-5-carboxylate.
- humectants including but not limited to: dibutyl phthalate; soluble collagen; sorbitol; or sodium 2-pyrrolidone-5-carboxylate.
- Other examples of humectants that may be used in practicing the present invention can be found in the CFTA Cosmetic Ingredient Handbook, the relevant portions of which are incorporated herein by reference.
- acceptable carriers in the present invention may optionally comprise one or more emollients including but not limited to: butane- 1,3-diol; cetyl palmitate; dimethylpolysiloxane; glyceryl monoricinoleate; glyceryl monostearate; isobutyl palmitate; isocetyl stearate; isopropyl palmitate; isopropyl stearate; butyl stearate; isopropyl laurate; hexyl laurate; decyl oleate; isopropyl myristate; lauryl lactate; octadecan-2-ol; caprylic triglyceride; capric triglyceride; polyethylene glycol; propane-1,2-diol; triethylene glycol; sesame oil; coconut oil; safflower oil; isoamyl laurate; nonoxynol-9; panthenol; hydrogen
- acceptable carriers used in the present invention may optionally comprise one or more penetration enhancers including but not limited to: pyrrolidones, for example 2-pyrrolidone; alcohols, such as ethanol; alkanols, such as decanol; glycols, such as propylene glycol, dipropylene glycol, butylene glycol; surfactants; or terpenes.
- penetration enhancers including but not limited to: pyrrolidones, for example 2-pyrrolidone; alcohols, such as ethanol; alkanols, such as decanol; glycols, such as propylene glycol, dipropylene glycol, butylene glycol; surfactants; or terpenes.
- an acceptable carrier can be a lotion that is topically applied.
- the lotion may comprise cabomer 981 , water, glycerin, isopropyl myristate, mineral oil, shea butter, stearic acid, glycol stearate, cetyl alcohol, dimethicone, preservatives, tea, and various ingredients of the formulations of the present invention.
- the formulations of the present invention may also contain various known and conventional cosmetic adjuvants so long as they do not detrimentally affect the desired skin improvement and moisturizing effects provided by the formulation.
- a formulation of the present invention can further include one or more additives or other optional ingredients well known in the art, which can include but are not limited to fillers (e.g., solid, semi-solid, liquid, etc.); carriers; diluents; thickening agents; gelling agents; vitamins, retinoids, and retinols (e.g., vitamin B 3 , vitamin A, etc.); pigments; fragrances; sunscreens and sunblocks; anti-oxidants and radical scavengers; organic hydroxy acids; exfoliants; skin conditioners; moisturizers; ceramides, pseudoceramides, phospholipids, sphingolipids, cholesterol, glucosamine, pharmaceutically acceptable penetrating agents (e.g., n-decylmethyl sulfoxide, lecithin
- the formulation can include additional inactive ingredients, including, but not limited to surfactants, co-solvents, and excipients.
- surfactants such as hydrophilic and hydrophobic surfactants, can be included in the formulations.
- Particular surfactants can be used based on the on the overall composition of the formulation and the intended delivery of the formulation.
- Useful surfactants include polyethoxylated (PEG) fatty acids, PEG-fatty acid diesters, PEG-fatty acid mono- and di-ester mixtures, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglycerized fatty acids, propylene glycol fatty acid esters, mixtures of propylene glycol esters-glycerol esters, mono- and diglycerides, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, polysaccharide esters, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters, lower alcohol fatty acid esters, ionic surfactants, and mixtures thereof.
- PEG polyethoxylated
- the formulations can also include co-solvents such as alcohols and polyols, polyethylene glycols ethers, amides, esters, other suitable co-solvents, and mixtures thereof.
- co-solvents such as alcohols and polyols, polyethylene glycols ethers, amides, esters, other suitable co-solvents, and mixtures thereof.
- the formulations can also include excipients or additives such as sweeteners, flavorants, colorants, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, odorants, opacifiers, suspending agents, binders, and mixtures thereof.
- the formulations of the present invention are topically or orally administered at least on a daily basis for a period of time sufficient to bring about the desired level of improvement in skin appearance, texture, and moisture.
- Topical application or oral administration of the formulations of the invention may continue for any suitable period of time. More specifically, within a few hours to within a few days of the initial application or ingestion, a user may notice the skin has an improved appearance, texture, and moisture.
- the frequency with which the formulations of the present invention should be applied or ingested will vary depending on the desired level improved appearance, texture, and moisture.
- the degree of cosmetic enhancement will vary directly with the total amount of composition used.
- Useful dosage forms can be prepared by methods and techniques that will be well understood by those of skill in the art and may include the use of additional ingredients in producing tablets, capsules, or liquid dosage forms.
- Example 1 Stimulation of Pro-Collagen synthesis using ingredients of the present invention
- Hs27 a human fibroblast cell culture and HEK, a human keratinocyte cell culture, were established in 96 well plates.
- the cells were exposed to various ingredients of the formulations of the present invention at concentrations of 1 ug/ml-10 ug/ml.
- the co-cultures were then incubated overnight.
- the following day supernatants were collected.
- the supernatants were analyzed for the presence of pro-collagen, a soluble precursor of collagen formed by fibroblasts in the process of collagen synthesis.
- Pro-collagen synthesis was assayed using commercially available ELISA kits.
- Table 1 shown below, illustrates the effect of Chia Seed oil and Opuntia Ficus lndica extract on collagen synthesis. The data are expressed as % control collagen from untreated control cells. Table 1 shows that when used alone, Chia Seed oil and Opuntia Ficus lndica extract are inducers of collagen synthesis.
- Example 2 Stimulation of Hyaluronic acid synthesis using ingredients of the present invention
- Hs27 a human fibroblast cell culture and HEK 1 a human keratinocyte cell culture, were established in 96 well plates. The cells were exposed to Opuntia Ficus lndica extract at concentrations of 1 ug/ml. The co-cultures were then incubated overnight. The following day supernatants were collected. The supernatants were analyzed for the presence of hyaluronic acid. Hyaluronic acid synthesis was assayed using commercially available ELISA kits. The protocol for this procedure is explained more fully by Lindqvist U., Chichibu K., Delpech B., Goldberg RL 1 Knudson W., Poole AR, Laurent TC. 1992. "Seven different assays of hyaluronan compared for clinical utility.” Clin. Chem. 38(1): 127-32, the entire contents of which are hereby incorporated by reference.
- Table 2 shown below, illustrates the effect of Opuntia Ficus lndica extract on hyaluronic acid synthesis. The data are expressed as % control hyaluronic acid from untreated control cells. Table 2 shows that Opuntia Ficus lndica extract is a potent inducer of Hyaluronic Acid synthesis.
- Example 3 Inhibition of lnterleukin-1 b synthesis using ingredients of the present invention
- Hs27 a human fibroblast cell culture and HEK, a human keratinocyte cell culture, were established in 96 well plates. The cells were exposed to Chia Seed oil at concentrations of 100 ug/ml. The co-cultures were then incubated overnight. The following day supernatants were collected. The supernatants were analyzed for the presence of lnterleukin-1 b. lnterleukin-1 b synthesis was assayed using commercially available ELISA kits. The protocol for this procedure is explained more fully by Allen-Hall L, Cano P, Arnason JT, Rojas R, Lock O, Lafrenie RM.
- Table 3 shows the effect of Chia Seed oil and a lipophilic extract of Opuntia Ficus lndica on lnterleukin-1b synthesis. The data are expressed as % control lnterleukin-1b from untreated control cells. Table 3 shows that Chia Seed oil and a lipophilic extract of Opuntia Ficus lndica reduced lnterleukin-1b synthesis.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880114867A CN101842089A (en) | 2007-11-01 | 2008-10-21 | Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
KR1020107009578A KR101497745B1 (en) | 2007-11-01 | 2008-10-21 | Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
JP2010533145A JP5525449B2 (en) | 2007-11-01 | 2008-10-21 | Methods for stimulating the synthesis of procollagen or collagen and hyaluronic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/982,122 | 2007-11-01 | ||
US11/982,122 US7722904B2 (en) | 2007-11-01 | 2007-11-01 | Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009058613A1 true WO2009058613A1 (en) | 2009-05-07 |
Family
ID=40588303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/080596 WO2009058613A1 (en) | 2007-11-01 | 2008-10-21 | Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid |
Country Status (5)
Country | Link |
---|---|
US (1) | US7722904B2 (en) |
JP (1) | JP5525449B2 (en) |
KR (1) | KR101497745B1 (en) |
CN (1) | CN101842089A (en) |
WO (1) | WO2009058613A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011115061A1 (en) * | 2010-03-17 | 2011-09-22 | 株式会社資生堂 | Hyaluronic acid production promoter |
EP2514403A1 (en) | 2011-04-20 | 2012-10-24 | Coty Germany GmbH | Cosmetic composition for increasing the collagen synthesis in the skin cells |
EP3815669A1 (en) | 2019-11-01 | 2021-05-05 | Weleda AG | Cosmetic composition comprising an opuntia ficus indica extract |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT507988B1 (en) * | 2009-01-15 | 2012-06-15 | Kaahee Res And Dev Gmbh | CACTUS FRUIT EXTRACT |
DE112009005131T5 (en) * | 2009-08-07 | 2012-09-13 | Alpes Pharmaeuticals Limitada | Topical drug for the treatment of psoriasis |
ES2364012B1 (en) * | 2009-12-11 | 2012-07-12 | José Antonio Novejarque Conde | BASE FORMULATION FOR COSMETIC PRODUCTS. |
US8318222B2 (en) * | 2010-02-19 | 2012-11-27 | Mary Kay, Inc. | Topical skin care formulation |
US8685472B2 (en) | 2010-03-01 | 2014-04-01 | Access Business Group International Llc | Skin whitening composition containing chia seed extract |
EP2613762B1 (en) | 2010-09-10 | 2018-10-17 | Mary Kay, Inc. | Topical skin care formulations comprising jaboticaba fruit pulp |
US20120201768A1 (en) * | 2010-09-10 | 2012-08-09 | Cheri Lynn Swanson | Cosmetic compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation |
WO2012050763A2 (en) | 2010-09-29 | 2012-04-19 | Access Business Group International Llc | Chia seed extract and related method of manufacture |
EP2658522B1 (en) | 2010-12-30 | 2019-07-31 | Mary Kay Inc. | Multi-purpose cosmetic compositions |
KR102044562B1 (en) * | 2011-05-10 | 2019-11-13 | 마리 케이 인코포레이티드 | cosmetic compositions |
US9402794B2 (en) | 2011-12-07 | 2016-08-02 | Mary Kay Inc. | Topical skin care formulation |
US8877259B2 (en) | 2012-02-09 | 2014-11-04 | Mary Kay Inc. | Cosmetic formulation |
ES2424294B1 (en) | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails |
US20130281913A1 (en) | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
CN111053730A (en) * | 2012-05-29 | 2020-04-24 | 玫琳凯有限公司 | Cosmetic composition |
CN102670469B (en) * | 2012-06-06 | 2013-10-30 | 广州舒泰生物技术有限公司 | Acne removing cosmetic and preparation method thereof |
JP2015528473A (en) | 2012-09-14 | 2015-09-28 | クロックス テクノロジーズ インコーポレイテッドKlox Technologies Inc. | Beauty biophotonic composition |
EP2962680A4 (en) * | 2013-02-28 | 2016-12-28 | Amorepacific Corp | Composition for maintaining efficacy of filler |
US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
US9186386B2 (en) | 2014-04-17 | 2015-11-17 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
CN106573055B (en) | 2014-06-09 | 2021-03-23 | 广东科洛克生物医药集团有限公司 | Silicone-based biophotonic compositions and uses thereof |
FR3029417B1 (en) * | 2014-12-08 | 2017-01-06 | Franck Margnat | ACTIVE COMPLEX FOR A COSMETIC PRODUCT AGAINST SKIN AGING |
KR20180030721A (en) * | 2015-08-10 | 2018-03-23 | 마리 케이 인코포레이티드 | Topical compositions |
EP3389624B1 (en) | 2015-12-18 | 2023-07-26 | Mary Kay Inc. | Topical cosmetic compositions |
US11135146B2 (en) | 2015-12-28 | 2021-10-05 | Klox Technologies Limited | Peroxide-less biophotonic compositions and methods |
CA3010886A1 (en) | 2016-01-11 | 2017-07-20 | Klox Technologies Limited | Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections |
EP3463268B1 (en) | 2016-05-23 | 2021-11-03 | Klox Technologies Limited | Biophotonic compositions and uses thereof |
US20190358327A1 (en) | 2016-12-23 | 2019-11-28 | Klox Technologies Inc. | Biophotonic compositions comprising lichen extract and their use to treat skin disorders |
CN110922888A (en) * | 2019-11-14 | 2020-03-27 | 西安和光明宸科技有限公司 | Preparation method of electronic component coating |
CN113749979A (en) * | 2021-10-13 | 2021-12-07 | 卡莱丽化妆品有限公司 | Nano-liposome, preparation method and application thereof, and anti-inflammatory repair cream, anti-inflammatory repair emulsion and anti-inflammatory repair spray |
CN115300580A (en) | 2022-04-25 | 2022-11-08 | 捷通国际有限公司 | Compositions and methods for inhibiting advanced glycation endproducts |
CN115404199B (en) * | 2022-11-01 | 2023-03-21 | 广州优特佳生物科技发展有限公司 | Application of activin B in promoting hyaluronic acid synthesis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6361806B1 (en) * | 2000-02-23 | 2002-03-26 | Michael P. Allen | Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
US20060147397A1 (en) * | 2002-11-07 | 2006-07-06 | Kose Corporation | Composition for preparation for external use on skin and method of using the same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU734341B2 (en) * | 1996-08-02 | 2001-06-14 | Shiseido Company Ltd. | Composition for enhancing hyaluronic acid productivity and method for preparing same |
JP4022911B2 (en) * | 1996-08-02 | 2007-12-19 | 株式会社資生堂 | Hyaluronic acid production capacity enhancer |
FR2757863B1 (en) * | 1996-12-27 | 1999-03-26 | Inovat Sarl | NOVEL BIOLOGICALLY ACTIVE SUBSTANCES, PROCESS FOR OBTAINING SAME AND COMPOSITIONS CONTAINING SAME |
FR2770843B1 (en) * | 1997-11-13 | 2000-01-14 | Lavipharm Lab | ASSOCIATION OF PLANT POLAR LIPID-LIPIDS, PROCESS FOR THE PREPARATION THEREOF AND ITS APPLICATIONS |
DE10034970B4 (en) * | 2000-07-19 | 2004-11-18 | Sanguibiotech Gmbh | An oxygen carrier, selected from hemoglobin or a preparation containing hemoglobin and myoglobin in the form of an emulsion, and its use as a cosmetic external and for the natural regeneration of the skin in the absence of oxygen |
JP2002068933A (en) * | 2000-08-25 | 2002-03-08 | Koei Kogyo Kk | Fibroblast proliferation stimulator |
JP2002212087A (en) * | 2001-01-22 | 2002-07-31 | Kose Corp | Skin care preparation |
US6555118B1 (en) * | 2001-02-22 | 2003-04-29 | Sarfaraz K Niazi | Pharmaceutical preparation for the treatment of topical wounds and ulcers |
JP4091825B2 (en) * | 2002-02-05 | 2008-05-28 | 株式会社コーセー | Skin preparation |
JP4091824B2 (en) * | 2002-02-05 | 2008-05-28 | 株式会社コーセー | Skin preparation |
DE10350194B4 (en) * | 2003-10-28 | 2005-11-10 | Bioplanta Arzneimittel Gmbh | Use of extracts from Opuntia for the treatment of depressive moods and disorders |
WO2005120174A2 (en) | 2004-05-24 | 2005-12-22 | Interactive Research Institute For Health Affairs | Omega-3 fatty acid compositions with honey |
FR2894828B1 (en) | 2005-12-21 | 2008-01-18 | Jean Alexis Grimaud | NEW COSMETOLOGICAL AND / OR DERMATOLOGICAL COMPOSITIONS BASED ON PROLINE DERIVATIVES AND USES THEREOF |
-
2007
- 2007-11-01 US US11/982,122 patent/US7722904B2/en active Active
-
2008
- 2008-10-21 KR KR1020107009578A patent/KR101497745B1/en active IP Right Grant
- 2008-10-21 CN CN200880114867A patent/CN101842089A/en active Pending
- 2008-10-21 JP JP2010533145A patent/JP5525449B2/en active Active
- 2008-10-21 WO PCT/US2008/080596 patent/WO2009058613A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6361806B1 (en) * | 2000-02-23 | 2002-03-26 | Michael P. Allen | Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
US20060147397A1 (en) * | 2002-11-07 | 2006-07-06 | Kose Corporation | Composition for preparation for external use on skin and method of using the same |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011115061A1 (en) * | 2010-03-17 | 2011-09-22 | 株式会社資生堂 | Hyaluronic acid production promoter |
JP2011195473A (en) * | 2010-03-17 | 2011-10-06 | Shiseido Co Ltd | Hyaluronic acid-production promotor |
EP2514403A1 (en) | 2011-04-20 | 2012-10-24 | Coty Germany GmbH | Cosmetic composition for increasing the collagen synthesis in the skin cells |
US9572768B2 (en) | 2011-04-20 | 2017-02-21 | Coty Germany Gmbh | Cosmetic composition for use in increasing the collagen synthesis in skin cells |
EP3815669A1 (en) | 2019-11-01 | 2021-05-05 | Weleda AG | Cosmetic composition comprising an opuntia ficus indica extract |
WO2021084136A1 (en) | 2019-11-01 | 2021-05-06 | Weleda Ag | Cosmetic composition containing an extract from opuntia ficus indica |
Also Published As
Publication number | Publication date |
---|---|
JP5525449B2 (en) | 2014-06-18 |
US7722904B2 (en) | 2010-05-25 |
KR101497745B1 (en) | 2015-03-02 |
CN101842089A (en) | 2010-09-22 |
JP2011503078A (en) | 2011-01-27 |
US20090117211A1 (en) | 2009-05-07 |
KR20100088669A (en) | 2010-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7722904B2 (en) | Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid | |
US10300102B2 (en) | Extract of aerial parts of oats | |
JP5922715B2 (en) | Composition for controlling and / or stabilizing conditions affecting the skin | |
KR101146206B1 (en) | Cosmetic Composition And Composition of Skin External Application | |
KR101059471B1 (en) | Cosmetic composition for skin aging | |
US9603789B2 (en) | Composition containing a natural extract | |
DE202012012784U1 (en) | Topical skin care formulations comprising plant extracts | |
KR101100678B1 (en) | Cosmetic Composition comprising plant extracts | |
KR102147833B1 (en) | A cosmetic composition for improving skin containing a peptide | |
KR20200088074A (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
KR102462347B1 (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
KR101223749B1 (en) | Composition for Improving Atopy Dermatitis Using a Extract of Humulus japonicus or a Extract of Quercus acuta | |
EP2055307B1 (en) | Active agent combinations made from anise fruit extract and white tea extract | |
KR20170130865A (en) | Composition for anti-inflammatory or moisturizing on skin comprising plant extract | |
KR20090075950A (en) | Therapeutical compositions for obstinate atopic dermatitis | |
KR102127771B1 (en) | A composition for antioxidation, anti-inflammation, antiaging or skin soothing comprising herb complex extracts | |
KR20090042073A (en) | Compositions of the specific herb extracted complex which has the function of alleviating the irritation and those of cosmetics for allergic skin containing it | |
KR102628844B1 (en) | Cosmetic composition for anti-oxidation, skin whitening and anti-wrinkle containing a mixed fermentation extracts of Wisteria floribunda flowers, Aralia elata flowers, Camellia japonica leafs and Camellia japonica flowers as effective component | |
KR102416652B1 (en) | Cosmetic composition for anti-irritation due to the particulate matter and improving skin conditions | |
KR102381251B1 (en) | Cosmetic composition for anti-oxidation, skin moisturizing, or improving of acne skin or skin trouble containing complex extract of Eriobotryae Folium | |
KR102208482B1 (en) | Cosmetic composition for improving skin troubles | |
KR101924356B1 (en) | Composition for anti-stretch mark effect on the skin containing extracts of salicornia herbacea, ecklonia cava and callistemon lanceolatus | |
KR101924355B1 (en) | Composition for anti-stretch mark effect on the skin containing extracts of salicornia herbacea and ecklonia cava | |
KR20060010918A (en) | Compositions of ointments controlling skin immune system containing specific herbal extract complex | |
WO2024054402A1 (en) | Composition and method for inhibiting elastase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880114867.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08843429 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20107009578 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010533145 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08843429 Country of ref document: EP Kind code of ref document: A1 |